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Abstract 
Neuroblastoma is the most common extracranial solid tumor found in children and            
accounts for 13-15% of all pediatric cancer deaths. Amplification of MycN is one of the               
strongest indicators of poor prognosis, is present in 50% of all high-risk cases of neuroblastoma,               
and has been detected in 30% of all cancers; while its role in neuroblastoma has not been clearly                  
elucidated, evidence suggests that it binds to the C-terminal domain of p53 and alters its response                
to genotoxic stress. The binding of p53 and MycN is a relatively novel discovery; more               
investigation into the role of p53-MycN binding can provide insight into neuroblastoma            
tumorigenesis and potentially other MycN-amplified cancers. This project sought to further           
investigate the role of MycN and p53 binding in neuroblastoma and to outline further research on                
the novel interaction.  
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1: Introduction 
Neuroblastoma is a neural-crest derived cancer that comprises 8-10% of pediatric cancers 
and up to 15% of all pediatric cancer deaths. Neuroblastomas tend to be highly heterogeneous 
and as a result, some patients’ tumors regress without chemotherapy while others undergo 
several aggressive therapy regimens. The most negative diagnostic factor in NB is the presence 
of MycN amplification, which is associated with high rates of progressive disease and low 
survival. MycN is a part of the Myc family of proteins, which also includes C-Myc and MycL, 
which is considered to be a family of proto-oncogenes found in many human cancers. Myc 
proteins form heterodimers with MAX to activate transcription; however, unbound Myc can act 
as a global amplifier of transcription. Typically, such a widespread increase in transcription and 
proliferation would trigger p53-mediated apoptosis; however, evidence suggests that cross-talk 
between p53 and MycN exists in neuroblastoma. 
Agarwal et al (2018) suggested a model for neuroblastoma in which MycN, when found 
in the excesses seen in MycN-amplified neuroblastoma tumors, binds to the C-terminal domain 
of p53. The study also provides evidence that p53’s transcriptional activity is altered in 
conditions wherein high levels of MycN are present as opposed to low-MycN conditions. 
Learning more about this novel interaction of p53 and MycN has the potential to reveal insight 
into the tumorigenesis of neuroblastoma and other MycN-amplified tumors. The goal of this 
project is to replicate and expand upon results discovered by the Shohet lab that describe the 
interaction of MycN and p53. Specifically, this project aims to examine the binding of p53 and 
MycN in various neuroblastoma models, to examine the C-terminal domain of p53 for 
post-translational modifications that may facilitate its binding to MycN, and to perform 
CUT&RUN chromatin profiling to confirm the results of Agarwal et al (2018) regarding p53 
response element binding when bound to MycN. 
Unfortunately, due to the closure of labs at both WPI and the University of Massachusetts 
Medical School in order to preserve personal protective equipment for clinicians, the final 
experiments were cut from the project plan and the last two objectives were unable to be met. 
However, the overarching goal of investigating the interaction of MycN and p53 in 
neuroblastoma was partially met prior to these closures, and robust interaction of the two 
proteins was observed in various models of neuroblastoma. It is the hope of the author that this 
work may be a foundation for future students to continue to research this  novel interaction and 
its implications on neuroblastoma.  
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2: Background 
In order to understand the roles of p53 and MycN in neuroblastoma, the development of               
neuroblastoma must be understood alongside the wild-type functions of p53 and MycN.  
2.1: Pediatric Neuroblastoma is a Neural Crest Derived Tumor 
Neuroblastoma arises as a result of malignancies in peripheral ganglia of the sympathetic             
nervous system. A majority (~60%) of tumors arise from the abdominal paraspinal ganglia, 30%              
from the adrenal medulla, and the remaining ~10% from ganglia in the chest, pelvis, head, or                
neck (Louis & Shohet, 2015). In addition to presenting in a variety of physical locations within                
the body, neuroblastoma tumors are highly heterogeneous and can exhibit a wide range of              
behavior; some patients’ tumors regress spontaneously while others have highly aggressive           
tumors that metastasize and resist treatment (Louis & Shohet, 2015). The biologic heterogeneity             
of these tumors can be explained in part by the complexity of neural crest development during                
embryogenesis.  
2.1.1: Neural Crest Development 
Neural crest cells are embryonic cells that are transiently present during the processes of              
gastrulation and neurulation; they migrate throughout the developing embryo and can           
differentiate into a wide range of derivative cell types (Bae and Saint-Jennet, 2014). The process               
of neural crest development begins when cells at the edges of the neural plate, or neural plate                 
border cells (NPBs), are induced to express a series of proteins including bone morphogenic              
protein (BMP), fibroblast growth factor (FGF), and Wingless/Int (Wnt); the expression of these             
proteins “primes” NPBs for differentiation into neural crest progenitors. Additionally, research           
has implicated all of these proteins in neuroblastoma tumorigenesis and differentiation           
(Tomolonis et al, 2017). These neural crest precursors are then committed to speciation into              
neural crest cells (NCCs) by two groups of transcription factors, early- and late-onset neural crest               
specifiers. Early-onset neural crest specifiers include c-Myc and its target Id3, proteins that help              
to control the cell cycle and are theorized to help NCCs to maintain their pluripotency               
(Tomolonis et al, 2017). Interestingly, c-Myc is closely related to MycN, which is widely viewed               
as the strongest negative prognostic indicator in neuroblastoma; both proteins are known to             
regulate a wide number of genes involved in pluripotency maintenance (Tomolonis et al, 2017).              
A large number of genes are considered to be late-onset neural crest specifiers (Sox9, Sox10,               
FoxD3, Snail2, and Twist1) that allow NCC’s to delaminate from the neuroepithelium,            
beginning the epithelial-to-mesenchymal transition (EMT) (Tomolonis et al, 2017). During the           
EMT, a series of changes to the NCCs occurs that decrease their adherence to neighboring cells                
and increase their motility (Taneyhill and Padmanabhan, 2014). NCCs then migrate throughout            
the embryo to their target locations, where they differentiate into their final cell types based on                
their position and origin (Bae and Saint-Jennet, 2014). Most, if not all, of these pathways have                
been shown to be dysregulated in neuroblastoma, contributing to tumor pathogenesis and            
differentiation. 
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2.1.2: Neuroblastoma Tumorigenesis 
Despite the origin of neuroblastomas from aberrant neural crest development, a single            
mutation responsible for all cases has not been identified. This in conjunction with the clinical,               
molecular, and pathologic heterogeneity of neuroblastoma tumors may signal that a range of             
molecular drivers are at play (Louis and Shohet, 2015). Stem cell-like populations within             
neuroblastomas have been shown to differentially express late-onset neural crest specifiers such            
as Sox10 and E-Cadherin (Hsu, Agarwal, et al, 2013), supporting the idea that cancer stem cells                
(CSCs) of neuroblastoma may correspond to different tumor phenotypes based on their            
precursors’ developmental stage (Louis and Shohet, 2015). On the whole, Louis and Shohet             
(2015) suggest that tumor-initiating CSCs may yield less or more malignant tumors based on the               
stage of neural crest development from which the CSCs are derived, with more differentiated              
CSCs yielding less malignant tumors. MycN amplification has been implicated in aggressive            
isotypes of neuroblastoma; this is not surprising due to its function of maintaining pluripotency              
(Tomolonis et al, 2017). 
2.1.3: Neuroblastoma Clinical Staging and Treatment  
As explained above, neuroblastoma exhibits an extremely wide range of activity in clinic;             
as such, not all neuroblastoma patients can be treated in the same way. In order to categorize                 
neuroblastoma patients for treatment, the International Neuroblastoma Staging System (INSS)          
was developed. Stages in the INSS were based upon the characteristics of tumors that were               
defined in surgery and can be found in Appendix A; however, staging according to this system                
was limited in scope. The currently-used International Neuroblastoma Risk Group Staging           
System (see Appendices B and C) provides staging categories and risk groups that consider a               
much wider range of variables in light of neuroblastoma’s heterogeneity (Louis and Shohet,             
2015). Ultimately, these categories are utilized to determine recommendations for treatment, the            
scope of which ranges widely from observation to chemotherapy, surgery, immunotherapy, and            
more. As stated above, MycN amplification is present in aggressive neuroblastoma tumors;            
patients with these tumors are frequently considered to have higher-stage disease. In this way,              
understanding the behavior of MycN can help to understand and, ultimately, treat those patients              
who are at the highest risk.  
2.2: p53 Plays a Critical Role in Preventing Cancer  
p53 is arguably one of the most well-known proteins in modern health science. The              
mutation of p53 is associated with over fifty percent of all cancers; of the tumors that do not                  
carry a p53 mutation, most experience p53 inactivation through another mechanism. (Horn and             
Vousden, 2007). It plays an important role in cellular responses to stress by triggering cell cycle                
arrest, senescence, or apoptosis. When stressful conditions such as hypoxia or DNA damage             
occur, p53 binds to response elements in DNA and induces the downstream expression of genes               
such as p21, a CDK inhibitor that prevents the cell from progressing through the cell cycle                
(Mello and Attardi, 2018). Figure 1 describes some of the traditional pathways in which p53               
activation is involved; however, recent research suggests that p53 has a wider reach within the               
body, affecting processes such as glycolysis, autophagy, and angiogenesis (Vousden and Lane,            
2007).  
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Figure 1: ​Activating stimuli and responses of p53 (Retrieved from Vousden and Lane, 2007) 
2.2.1: Molecular Structure of p53  
P53 is composed of 393 amino acids divided into five main domains: the transactivation              
domain, the proline-rich domain, the DNA binding domain, the tetramerization domain, and the             
C-terminal domain. Malignancy-causing mutations are most frequently found within the DNA           
binding domain; mutant p53 proteins with these mutations typically have both altered            
conformation and diminished DNA binding abilities (Dai and Gu, 2010). The transactivation            
domain is crucial for p53’s binding to MDM2 and its human analog HDM2, which will be                
discussed later and plays an active role in suppressing p53’s activity until the detection of               
cellular stress (Lee, Martinez-Yamout, Dyson, and Wright, 2010). The active form of p53 in              
complex with DNA is a tetramer; the tetramerization domain is responsible for the binding of               
dimerization of p53 monomers and the subsequent dimerization of these dimers (Aramayo et al.,              
2011). The function of the C-terminal domain has been subject to debate in recent years;               
however, research suggests that it facilitates site-specific binding to DNA response elements            
(Laptenko et al., 2015).  
 
 
 
Figure 2: ​Structure of p53 and its domains (Adapted from Dai and Gu, 2010) 
 
 
In order for p53 to complex with DNA, two molecules must first dimerize; the dimers               
then dimerize along with DNA to form the complex. However, the arrangement of this tetramer               
has been subject to debate and several Cryo-EM studies. Figure 3 depicts an accepted              
configuration for the p53 tetramer in complex with DNA in panel C, in which the C-terminal                
domains of two of the four monomers are at the core of the complex in order to stabilize the                   
complex through additional interactions between the p53 tetramer and DNA. Additionally, the            
N-termini are located further from the core in order to allow for interactions with other proteins                
such as Mdm2, MdmX, and additional cofactors. (Aramayo et al., 2011).  
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Figure 3: ​Structure of a p53 core bound to DNA (Retrieved from Malecka, Ho, and Marmorstein, 2009).  
 
2.2.2: p53 Activation 
In its inactive state, p53 is bound to DNA in its tetramer formation; however, its activity                
is repressed by the binding of Mdm2 and MdmX to the transactivation domains of the N termini.                 
However, under stressful conditions within the cell, p53 undergoes a series of posttranslational             
modifications that prevent the binding of Mdm2 and MdmX, including acetylation of specific             
lysines in the DNA-binding domain and the phosphorylation of serines in the N- and C-termini.               
Specifically, the phosphorylation of serines 15 and 20 (S15/20) has been clearly implicated in the               
prevention of Mdm2 binding to p53 (Dai & Gu, 2010). When Mdm2 and MdmX are prevented                
from binding to the p53-DNA complex, several transcription factors, and cofactors are recruited             
alongside RNA polymerase II to begin the transcription of a variety of genes. Stress response               
pathways are activated according to the binding of the p53 complex to their specific response               
elements (Dai & Gu, 2010). Figure 4 provides a visual representation of the p53 activation               
pathway.  
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Figure 4: ​Activation of p53 transcriptional activity (Retrieved from Dai and Gu, 2010) 
 
2.3: MycN Plays a Role in Neuroblastoma Tumorigenesis 
The Myc family of proteins, including C-Myc and MycN, are global activators of             
transcription that are crucial for early embryonic development (Yoshida, 2018). It is a basic              
helix-loop-helix transcription factor that must form heterodimers with its binding partner, MAX,            
in order to bind E-box sequences (Agarwal et al, 2018). However, the amplification of MycN has                
been tied to nearly 30% of all cancers (Schaub et al, 2018). In neuroblastoma, it is present in                  
50% of high-risk cases, while patients whose tumors have low levels of MycN expression              
experience better responses to chemotherapy and higher survival rates (Agarwal et al, 2018).  
2.3.1: A proposed mechanism for MycN’s activity in neuroblastoma 
The exact mechanism of MycN’s activity within neuroblastoma tumors has not yet been             
defined. In MycN amplified tumors, MAX is not amplified; this may indicate that MycN              
functions independently of MAX in these tumors (Agarwal et al, 2018). Interestingly, p53 is              
typically wild-type at the time of diagnosis in most patients despite MycN functioning to drive               
proliferation and alter DNA damage responses; these functions would typically drive p53 to             
initiate apoptosis (Agarwal et al, 2018). As stated in 2.2.1, p53’s binding to DNA response               
elements is facilitated by the C-terminal domain (CTD). Agarwal et al (2018) identified a direct               
interaction of MycN and the p53 CTD that affects the transcriptional responses of both MycN               
and p53. Additionally, Wang et al (2017, 2018) identified that post-translational modifications            
such as acetylation of the p53 CTD affect the binding of p53 to DNA and certain proteins. The                  
following report seeks to replicate and expand upon the results obtained by Agarwal et al (2018);                
specifically, this report seeks to confirm and further explore the direct binding relationship             
between MycN and p53 and the potential effects of p53’s post-translational modifications on the              
binding relationship. 
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3: Materials and Methods 
The following section details the materials and methods utilized throughout the entirety            
of the project to obtain the results described in Section 4. A complete list of reagents can be                  
found in Appendix D. 
3.1: Cell Culture 
The human neuroblastoma cell lines JF, MycN3 Tet-On, and NGP were maintained in             
RPMI medium containing 10% fetal bovine serum (FBS).  
3.2: Western Blotting 
Whole-cell lysates were collected and sonicated. The concentration of each lysate was            
determined via BCA assay (Thermo Fisher). Protein samples were boiled in Laemmli sample             
buffer, separated by SDS-PAGE using 14% tris-glycine gels, and transferred to a PVDF             
membrane. The membrane was blocked for 20 minutes, incubated with the primary antibody             
overnight at 4℃, washed with TBST for 20 minutes, incubated with the secondary antibody for               
one hour at room temperature, and imaged.  
3.3: Co-Immunoprecipitation Assays 
Crude protein extract from treated cells was prepared. Cells were lysed using 2X lysis              
buffer (See Appendix X for buffer formulation) and sonicated. Protein G Dynabeads (Invitrogen)             
were incubated for 1h at 4℃ with ɑ-p53 mouse antibody (DO1, Santa Cruz). One to three                
milligrams of crude protein extract was incubated overnight with 40 μL of mAb-bound beads at               
4℃. Following three washes with 1X lysis buffer 1, protein samples were eluted by boiling               
beads in Laemmli sample buffer, separated by SDS-PAGE, and analyzed via Western blot. 
3.3: Mass Spectrometry and Post-Translational Modification Analysis 
Crude protein extract from etoposide-treated (20 uM for 8 hours) NGP cells were             
prepared and immunoprecipitated for MycN according to the procedure listed in 3.3. The             
immunoprecipitated samples were eluted by boiling beads in Laemmli sample buffer and            
separated by SDS-PAGE. The band corresponding to p53 would have been cut out of the gel and                 
sent to the WPI Mass Spectrometry Core, PI Scott Shaffer, for LC-MS/MS and post-translational              
modification analysis. 
3.4: CUT&RUN Chromatin Profiling 
The procedure described in Hainer et al (2019), omitted here due to its length, would               
have been used for CUT&RUN chromatin profiling using the ɑ-p53 mouse antibody (DO1,             
Santa Cruz).  
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4: Goals and Objectives  
The following report seeks to indicate that the binding of MycN and p53 plays a role in 
neuroblastoma while further exploring the interaction of the two molecules. This will be 
accomplished through examination of the procedures and findings outlined in Agarwal et al 
(2018) and can be summarized by the following main goal of this report: 
 
Main Goal: ​To replicate and expand upon the findings of Agarwal et al (2018) by further 
investigating the relationship between MycN and p53 and the impacts of this interaction 
in neuroblastoma. 
 
In order to accomplish this main goal, three supporting objectives have been created and are 
listed and rationalized below.  
 
Objective 1:​ To determine the extent of MycN and p53 binding in various models of 
neuroblastoma and to determine the conditions which yield the most robust indication of 
endogenous binding of MycN and p53.  
 
Before expanding upon the results obtained by Agarwal et al (2018), the preliminary procedures 
of this project should focus upon replicating the binding interaction of MycN and p53 in the first 
cell line utilized by Agarwal et al (2018) and at least two other cell lines. Additionally, in order 
to proceed to the remaining objectives, determining the conditions which consistently yield the 
most robust interaction of MycN and p53 is crucial.  
 
Objective 2:​ To further examine the binding interaction of MycN and p53 by analyzing 
the post-translational modifications present in the C-terminal domain of MycN-bound 
p53. 
 
There is still much to be discovered about the relationship between MycN and p53. It is widely 
known that post-translational modifications of specific residues in p53 are vital to p53’s 
functionality, and it has been suggested that the typical post-translational modifications of p53 
are dysregulated in cancer tumorigenesis (Dai & Gu, 2010). Additionally, a wide number of 
post-translational modifications in p53 are localized to the C-terminus, which is also the location 
of MycN binding. By analyzing the post-translational modifications of MycN-bound p53, more 
can be learned about the interaction of the two molecules and whether or not a specific signature 
of post-translational modifications is required for the binding of MycN to p53’s C-terminus.  
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Objective 3:​ To investigate the chromatin binding profile of the MycN-p53 complex 
through the novel chromatin profiling technique CUT&RUN.  
 
Agarwal et al (2018) utilizes ChIP-seq to demonstrate the binding of the MycN-p53 complex at 
both p53 response elements and MycN E-boxes for a small number of genes. The use of 
CUT&RUN, a cheaper protocol that generates less background noise, can help to confirm and 
expand upon these results.   
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5: Results, Next Steps, and Discussion 
The following section describes the results obtained by this project and discusses their             
importance in the context of neuroblastoma.  
5.1: p53 and MycN Are Binding Partners 
In order to validate the results of Agarwal et al (2018) and complete Objective #1,               
co-immunoprecipitations for p53 and MycN were performed under various conditions. 
5.1.1: p53 and MycN binding in MycN3 cells 
In order to most closely recreate the conditions used by Agarwal et al (2018), MycN3, a                
cell line with a tetracycline-controlled activator for MycN expression, was utilized. After a             
time-course assay using the dosage of doxycycline described in Agarwal et al (2018), it was               
determined that maximum expression of both p53 and MycN would occur between 6 and 10               
hours of treatment. MycN3 cells were then treated under five conditions (untreated, doxycycline             
(1ug/mL), etoposide (20μM), doxycycline and etoposide for 6h, doxycycline and etoposide for            
10h); p53 was then immunoprecipitated. As seen below, while the whole-cell lysate shows a              
large amount of MycN present, there is no MycN in the immunoprecipitated samples. The blot               
was re-blotted with larger amounts of primary antibody and exposed for a longer period of time,                
but there was still no signal indicating the presence of MycN in the blot (data not shown). At this                   
time, it was determined that replicating the experiment in a cell line wherein MycN did not                
require doxycycline induction would yield better results and a more accurate depiction of the              
interactions of MycN and p53 in neuroblastoma tumors.  
 
Figure 5: p53 and MycN binding in MycN3 cells (A) MycN3 cells were treated with 1 ug/mL doxycycline for                   
varying amounts of time to determine the treatment condition leading to maximum MycN expression. (B) MycN3                
cells were treated with 20 μM etoposide in order to determine the ideal treatment conditions for maximum p53                  
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expression. ​(C) MycN3 cells were treated under various conditions to determine the best conditions for p53 and                 
MycN co-immunoprecipitation. 
5.1.2: p53 and MycN binding in JF cells 
After a time-course and dose-response assay, it was determined that the proper dosage of              
etoposide treatment to maximize expression of both p53 and MycN was 20 μM for 6 hours                
(Figure 6A). Additionally, a series of ten lysis buffers was tested in order to determine the most                 
effective lysis buffer to maximize protein concentration in the whole-cell lysate (See Appendix             
X for lysis buffer compositions). Bands in Figure XB are present, indicating weak interactions of               
p53 and MycN; however, the slight increase in band intensities in the lanes corresponding to               
lysis buffers 7, 9, and 10 provides a basis for further comparison of these lysis buffers for                 
co-immunoprecipitation.  
 
 
Figure 6: p53 and MycN binding in JF cells ​(A) ​JF cells were treated with either etoposide under varying                   
treatment conditions to determine the ideal treatment condition for maximum MycN and p53 expression. ​(B) ​JF cells                 
were lysed with various lysis buffers and immunoprecipitated in order to determine the lysis conditions to maximize                 
co-immunoprecipitation protein concentrations.  
 
5.1.3: p53 and MycN binding in NGP cells 
In order to determine if the results seen in 5.1.2 were replicable in other NB cell lines, the                  
binding of MycN and p53 was investigated in the neuroblastoma cell line NGP. Cells were               
treated with 20 μM etoposide for 8h; the initial NGP experiment compared the four lysis buffers                
discussed in section 5.1.2 (Buffers 1, 7, 9, 10). Immunoprecipitation was performed for all four               
conditions utilizing both p53 (ms) and MycN (ms) antibodies. As can be seen in Figure X, the                 
immunoprecipitations yielded a small amount of protein corresponding to very faint bands; of             
the bands seen, lysis buffers 1 and 7 were chosen for additional analysis. In order to hopefully                 
strengthen the bands seen in the immunoprecipitations, the following immunoprecipitations seen           
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in Figure 7B were performed using a MycN rabbit antibody. As can be seen, the ​α-MycN (rb)                 
immunoprecipitation showed a much more robust interaction between p53 and MycN than had             
been seen in previous experiments. For this reason, the remaining experiments requiring            
co-immunoprecipitations utilized the MycN rabbit antibody.  
 
 
Figure 7: p53 and MycN binding in NGP cells (A) ​Immunoprecipitations for p53 (left) and MycN (right) utilizing                  
the most successful lysis buffers from 4.1.2. ​(B) Immunoprecipitation for MycN utilizing a rabbit antibody as                
opposed to a mouse antibody. 
5.1.4: p53 and MycN are binding partners, summarized 
The data shown in Section 4.1 indicate that p53 and MycN do participate in a binding                
relationship in various models of neuroblastoma. These preliminary results indicate that it is             
possible that the interaction in the context of these cell lines is weaker than first described;                
however, further work should help to indicate the degree of this interaction.  
5.2: Next Steps 
Unfortunately, due to the onset of the SARS-CoV-2 outbreak, the labs at WPI and              
UMMS were closed to preserve personal protective equipment for clinicians. In light of these              
closures, the initially-planned mass spectrometry and CUT&RUN procedures were unable to be            
performed within the time frame of this project. This section will discuss future directions for               
this project should another student be interested in continuing to study the interaction between              
MycN and p53. 
5.2.1: Mass Spectrometry for Analysis of Post-Translational Modifications 
As discussed in Section 4: Goals and Objectives, Objective #2 centered around the             
investigation of MycN-bound p53’s post-translational modifications. Due to the importance of           
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post-translational modifications for p53’s function and the localization of several important           
post-translational modifications to the C-terminus of p53, it is possible that the post-translational             
modification profile of p53 helps to contribute to its interaction with MycN. The University of               
Massachusetts Medical School’s Mass Spectrometry facility offers a workflow that utilizes           
LC-MS/MS to analyze the post-translational modifications of a protein. In order to determine             
MycN-bound p53’s post-translational modifications, the following experimental setup should be          
utilized: Treat either NGP or JF cells with 20 µM etoposide for 8 hours and follow the                 
co-immunoprecipitation protocol described in section 3.3; the immunoprecipitation should utilize          
the ɑ-MycN rabbit antibody from Cell Signaling Technologies. The immunoprecipitate should           
then be separated via SDS-PAGE and stained with Coomassie blue. The band corresponding to              
p53 should then be cut out of the gel and transported to the University of Massachusetts Medical                 
School’s Mass Spectrometry facility for analysis.  
5.2.2: CUT&RUN Chromatin Profiling 
The findings demonstrated by Agarwal et al (2018) utilized ChIP-qPCR to investigate            
MycN and p53 binding at a select number of genes,including p21, CHEK1, SESN1, and CDC6.               
While ChIP has been the gold standard for chromatin profiling for a long time, the use of                 
CUT&RUN yields better resolution results, is more efficient, and is much more cost-effective.             
The role of CUT&RUN in this project would have hopefully been to examine binding of the                
MycN-p53 complex at a wider variety of loci than the original publication due to its ability to                 
examine more loci at a lower cost. For example, the paper mentions over 90 genes pulled from                 
MycN-ChIP-seq and p53-ChIP-seq databases that contain either MycN E-boxes or p53 response            
elements. Examining the potential binding of the MycN-p53 complex at any number of these              
genes, including the original four genes, has the potential to confirm that Agarwal et al’s (2018)                
conclusion that the MycN-p53 complex does indeed bind to both p53 RE’s and MycN E-boxes,               
altering p53’s binding activity.  
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6: Conclusion 
The mechanisms underlying neuroblastoma, a neural-crest derived cancer accounting for          
up to 10% of pedric cancers, are not well defined. Previous research has suggested that a wide                 
range of molecular players contribute to the tumorigenicity of neuroblastoma; one such            
molecular driver is MycN. In fact, MycN amplification is widely considered to be the most               
negative prognostic factor in neuroblastoma. Recent research has implicated a novel interaction            
of MycN with the tumor suppressor protein p53 in MycN-amplified models of neuroblastoma.             
This interaction is of great interest and has been proposed to be a potential explanation for                
MycN-amplified neuroblastoma’s modified response to chemotherapy and genomic instability.         
This report sought to further investigate this interaction in order to learn more about the               
mechanisms underlying neuroblastoma.  
The goal of further investigating the relationship between MycN and p53 remained the             
central focus throughout the duration of this project. However, with the transition to remote              
learning and the closure of academic labs due to SARS-CoV-2 pandemic, the methods of              
achieving this goal changed. Instead of performing the experimental work that would have led to               
the achievement of the final two objectives, the rationale and experimental outlines for these              
objectives were outlined above in section 5.2. This information can be utilized by students in the                
future who wish to continue to investigate the interaction of MycN and p53. However, the first                
objective of the project, determining the conditions and cell lines which demonstrate the most              
robust endogenous interaction of MycN and p53, was met. There is still some room to refine the                 
co-immunoprecipitation protocol in order to maximize its efficiency and the amount of            
pulled-down proteins, however, the protocol was sufficient for the purposes of this project.  
All in all, while this project may have been unfortunately cut short, the goal of further                
exploring the MycN-p53 interaction was met, even if to a smaller extent than originally planned.               
It is the author’s hope that future students are able to utilize this foundational research to further                 
investigate the complexities of this interaction and its further implications on neuroblastoma.   
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Appendices 
Appendix A: International Neuroblastoma Staging System  
Stage Surgical Characteristics 
Stage I Small, localized tumors; completely resected 
Stage II Small tumors; could not be completely 
resected; may or may not have had lymph 
node involvement 
Stage III Large tumors; crossed anatomic midline; 
could not be completely resected 
Stage IV Metastatic disease 
Stage IVS Metastatic disease in patients under one year; 
metastases confined to liver, skin, bone 
marrow 
Adapted from Louis and Shohet, 2015 
Appendix B: International Neuroblastoma Risk Group (INRG) Staging System 
Stage Definition 
L1 Localized tumor not involving vital structures as defined by the list of 
image-defined risk factors and confined to one body compartment 
L2 Locoregional tumor with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months with metastases 
confined to skin, liver, and/or bone marrow 
 
Retrieved from Louis and Shohet, 2015 
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Appendix C: International Neuroblastoma Risk Group (INRG) consensus        
pretreatment classification schema  
INRG 
Stage 
Age 
(mo) 
Histologic 
category 
Grade of 
tumor, 
differentiation 
MycN 11q 
abberation 
Ploidy Pre-treatm
ent risk 
group 
L1/L2 Any GN maturing 
or GNB 
intermixed 
Any Any Any Any A Very low 
L1 Any Any, except 
GN maturing 
or GNB 
intermixed 
Any NA 
Amp 
Any Any B Very low 
K High 
L2 <18 Any, except 
GN maturing 
or GNB 
intermixed 
Any NA 
NA 
No 
Yes 
Any D Low 
G 
Intermediate 
L2 >18 GN nodular; 
Neuroblastoma 
Differentiating 
Differentiating 
Poorly 
differentiated or 
undifferentiated 
NA 
NA 
NA 
Amp 
No 
Yes 
Any E Low 
H 
Intermediate 
H 
Intermediate 
N High 
M <18 
<12 
12 to 
<18 
<18 
≥18 
Any Any NA 
NA 
NA 
Amp 
Any Hyperdipl
oid 
Diploid 
Diploid 
F Low 
J 
Intermediate 
J 
Intermediate 
O High 
P High 
MS <18 Any Any NA 
NA 
Amp 
No 
Yes 
 C Very low 
Q High 
R High 
 
Retrieved from Louis and Shohet, 2015 
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Appendix D: Lysis Buffer Compositions  
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